Oxford Cannabinoid Tech.Holdings Data from pre-clinical study show positive results (9363D)
March 08 2022 - 2:00AM
UK Regulatory
TIDMOCTP
RNS Number : 9363D
Oxford Cannabinoid Tech.Holdings
08 March 2022
8 March 2022
Oxford Cannabinoid Technologies Holdings plc
("OCTP", or the "Company")
Data from pre-clinical study of OCT461201 shows positive
results
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB:
OCTHF), the pharmaceutical company developing prescription
cannabinoid medicines targeting the US$ multi-billion pain market
is pleased to announce positive results from a pre-clinical pain
study for its lead compound, OCT461201, targeting the global
Chemotherapy Induced Peripheral Neuropathy ("CIPN") treatment
market valued at US$1.61bn in 2020 and forecasted to reach
US$2.37bn by the year 2027.
CIPN is a peripheral neuropathy resulting from the neurotoxic
effects of common chemotherapeutic drugs. The hallmarks of CIPN are
pain, numbness and tingling in the extremities. On average, an
estimated 60 per cent. of people undergoing chemotherapy are
affected by CIPN at 3 months. CIPN can be progressive and enduring,
leading to years of debilitation and suffering.
The results from OCTP's recent study show that OCT461201
successfully reduces pain in a pre-clinical animal model of CIPN
induced by paclitaxel, a widely used chemotherapy agent. Two common
symptoms of CIPN are pain caused by innocuous stimuli, like light
touch (mechanical allodynia) and heat or cold (thermal
hyperalgesia). In the study, OCT461201 significantly reduced pain
from both mechanical allodynia and thermal hyperalgesia compared to
untreated animals.
Globally, there is an urgent need for new therapies to treat
CIPN as there are currently no approved therapies for this
condition. The current standard of care is the off-label use of
gabapentinoids (gabapentin and pregabalin) and antidepressants
(e.g. duloxetine), drugs associated with serious side effects.
Furthermore, in some cases their overall clinical effectiveness is
inadequate, leaving cancer patients in pain, with a reduced quality
of life and the prospect of having to change or stop their
chemotherapy altogether.
Commenting on the results of the experiment, OCTP Chief
Executive John Lucas said:
"To obtain such a positive result in this study is significant
and provides further evidence that OCT461201 could be an effective
therapy in the treatment of CIPN in cancer patients. Based on
previously completed pre-clinical safety experiments, the Directors
believe the administered dose of OCT461201 could have been
increased by over three times. The results of this study
demonstrate the opportunities open to OCT461201 in treating a major
and common side effect experienced by so many cancer patients and
we are more excited than ever to be starting phase 1 clinical
trials early next year. These latest results reaffirm the potential
of OCT461201 across multiple indications."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
Harbor Access LLC (US/OTCB enquiries) +1 (203) 862 0492
Jonathan Paterson Richard.Leighton@harboraccessllc.com
Richard Leighton
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc is the holding
company of Oxford Cannabinoid Technologies Ltd, a pharmaceutical
company developing prescription cannabinoid medicines for approval
by key medicines regulatory agencies worldwide and targeting the U$
multi-billion pain market (together the "Group"). Cannabinoids are
compounds found in the cannabis plant that have been shown to have
a range of therapeutic effects on the body, including pain relief.
The Group has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with clinical trials scheduled for Q1 2023. The Group's
product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of
rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners. ( https://www.oxcantech.com/)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESUPUPCWUPPGBM
(END) Dow Jones Newswires
March 08, 2022 02:00 ET (07:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Apr 2023 to Apr 2024